Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease

@article{Schreiber2000SafetyAE,
  title={Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease},
  author={S. Schreiber and R. Fedorak and O. H. Nielsen and G. Wild and C. Williams and S. Nikolaus and M. Jacyna and B. Lashner and A. Gangl and P. Rutgeerts and K. Isaacs and S. V. Deventer and J. Koningsberger and M. Cohard and A. Lebeaut and S. Hanauer},
  journal={Gastroenterology},
  year={2000},
  volume={119},
  pages={1461-1472}
}
Abstract Background & Aims: Interleukin (IL)-10 is a cytokine with potent anti-inflammatory properties. We investigated the safety and efficacy of different doses of human recombinant (rhu)IL-10 in patients with Crohn's disease (CD). Methods: A prospective, multicenter, double-blind, placebo-controlled study was conducted in 329 therapy-refractory patients with CD. Clinical improvement was defined by a reduction of the Crohn's Disease Activity Index (CDAI) by 100 points or more and clinical… Expand
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
TLDR
Subcutaneous rhuIL-10 administered daily for 28 days to patients with mild to moderately active Crohn's disease is safe, well-tolerated, and shows clinical and endoscopic improvement. Expand
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ
TLDR
High doses of IL-10 upregulate the production of IFN-γ and neopterin, which may be responsible for the lack of efficacy of high doses ofIL-10 in the treatment of CACD and MCD. Expand
Randomized, Double Blind Controlled Trial of Subcutaneous Recombinant Human Interleukin-11 Versus Prednisolone in Active Crohn's Disease
TLDR
RhIL-11 is well tolerated but significantly inferior when compared to prednisolone in short-term remission induction in patients with active CD, and both treatments appeared to be poor in maintaining remission over a period of 3 months. Expand
Recombinant human interleukin 10 for induction of remission in Crohn's disease.
TLDR
A systematic review shows that interleukin 10 does not increase the number of remissions, but increases the rate of withdrawal due to adverse events relative to placebo, and although further research may have an impact on point estimates of efficacy further randomized trials are unlikely to be undertaken. Expand
Safety of biologics in inflammatory bowel disease
TLDR
Two recent trials observed high efficacy of infliximab in inducting and maintaining clinical remission, mucosal healing, and corticosteroid-sparing effects in patients with moderate to severe UC. Expand
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease.
TLDR
The consistency of results among different assessment methods supports the efficacy of ova-Tregs; this immune therapy approach warrants further clinical and mechanistic studies in refractory CD. Expand
Safety of biologic therapy.
Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonalExpand
IL-17/23, potential targets for Crohn’s disease
Biological agents have profoundly changed the therapeutical management of Crohn’s disease and ulcerative colitis, the major clinical subentities of inflammatory bowel disease (IBD). In the gutExpand
Interleukin-12 Antagonists as New Therapeutic Agents in Inflammatory Bowel Disease
TLDR
The available data and experiences concerning these principles are presented in this review and anti-IL-12 strategies seem to play a promising role because of the central position of this Th1-inducing cytokine in the inflammatory cascade. Expand
Why interleukin-10 supplementation does not work in Crohn's disease patients.
TLDR
It is concluded that IL-10 supplementation is not a one size fits all treatment and if the correct population of patients is chosen then IL- 10 supplementation could be of benefit. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
TLDR
Subcutaneous rhuIL-10 administered daily for 28 days to patients with mild to moderately active Crohn's disease is safe, well-tolerated, and shows clinical and endoscopic improvement. Expand
Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.
TLDR
Results indicate that IL-10 administered as a daily bolus injection over 1 week is safe and well tolerated and may be clinically efficacious in Crohn's disease. Expand
Mechanisms in failure of infliximab for Crohn's disease
TLDR
Infliximab greatly improved clinical symptoms in 88% of patients with Crohn's disease after 1 week and reactivation of the mucosal and the systemic immune system preceded clinical relapse. Expand
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.
TLDR
A single 5 mg/kg infusion of CDP571 reduced disease activity in Crohn's disease at 2 weeks, suggesting that antibody neutralisation of TNF alpha is a potentially effective strategy in the management of Crohn’s disease. Expand
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease
TLDR
A single 5 mg/kg infusion of CDP571 reduced disease activity in Crohn's disease at 2 weeks, suggesting that antibody neutralisation of TNFα is a potentially effective strategy in the management of Crohn't disease. Expand
IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis.
TLDR
The data support a therapeutic role for IL-10 in the treatment of RA as a result of its anti-inflammatory and immunoregulatory properties and a trend towards efficacy with a good safety profile. Expand
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
TLDR
Investigations demonstrate the major importance of IL-10 in psoriasis and show thatIL-10 administration represents a new therapeutic approach, and is the first report on IL- 10 therapy for cutaneous disorders. Expand
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
TLDR
A 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 patients with moderate-to-severe Crohn's disease that was resistant to treatment, finding clinical response, the primary end point, was a reduction of 70 or more points in the score on theCrohn's Disease Activity Index at four weeks. Expand
Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.
TLDR
IL-10 down-regulates the enhanced secretion as well as messenger RNA levels of proinflammatory cytokines by IBD mononuclear phagocytes in vitro and in vivo and can restore diminished in vitro IL-1 receptor antagonist/IL-1 beta ratios in IBD to normal levels. Expand
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration.
TLDR
It is indicated that pretreatment with rhIL-10 reduces endotoxin-induced febrile responses, cytokine responses, and granulocyte accumulation in lungs, while in this acute model post-treatment with rh IL-10 exerts limited anti-inflammatory effects. Expand
...
1
2
3
4
5
...